Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors
- 23 July 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Bone and Mineral Metabolism
- Vol. 34 (5), 526-531
- https://doi.org/10.1007/s00774-015-0702-2
Abstract
The increasing number of osteoporosis patients is a pressing issue worldwide. Osteoporosis frequently causes fragility fractures, limiting activities of daily life and increasing mortality. Many osteoporosis patients take numerous medicines due to other health issues; thus, it would be preferable if a single medicine could ameliorate osteoporosis and other conditions. Here, we screened 96 randomly selected drugs targeting various diseases for their ability to inhibit differentiation of osteoclasts, which play a pivotal role in development of osteoporosis, and identified methotrexate (MTX), as a potential inhibitor. MTX is currently used to treat sarcomas or leukemic malignancies or auto-inflammatory diseases such as rheumatoid arthritis (RA) through its anti-proliferative and immunosuppressive activities; however, a direct effect on osteoclast differentiation has not been shown. Here, we report that osteoclast formation and expression of osteoclastic genes such as NFATc1 and DC-STAMP, which are induced by the cytokine RANKL, are significantly inhibited by MTX. We found that RANKL-dependent calcium (Ca) influx into osteoclast progenitors was significantly inhibited by MTX. RA patients often develop osteoporosis, and osteoclasts are reportedly required for joint destruction; thus, MTX treatment could have a beneficial effect on RA patients exhibiting high osteoclast activity by preventing both osteoporosis and joint destruction.Keywords
This publication has 26 references indexed in Scilit:
- HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosisProceedings of the National Academy of Sciences of the United States of America, 2013
- Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor functionJCI Insight, 2012
- L-type Ca2+ channel agonist inhibits RANKL-induced osteoclast formation via NFATc1 down-regulationLife Sciences, 2011
- The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasisThe Journal of Experimental Medicine, 2010
- TRPV4-Mediated Calcium Influx Regulates Terminal Differentiation of OsteoclastsCell Metabolism, 2008
- T cells in rheumatoid arthritisArthritis Research & Therapy, 2008
- Endocrine Regulation of Energy Metabolism by the SkeletonCell, 2007
- BONE MASS MEASUREMENT AND BONE METABOLISM IN RHEUMATOID ARTHRITIS: A REVIEWRheumatology, 1996
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisThe New England Journal of Medicine, 1985
- Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapyCancer, 1973